TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36181412

Group type: EXPERIMENTAL
Intervention: Standard treatment plus FMT therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard treatment plus FMT therapy with 3 administrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard treatment plus FMT therapy with 6 administrations
Number of subjects: 0
Study: 34120649

Group type: EXPERIMENTAL
Intervention: CFL-TB (mobile health intervention using interactive voice response technology)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 274
Study: 32111579

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left PFC (1.5 mA, 5-cm x 5-cm electrodes) with concurrent cathodal tDCS over the right PFC during emotion regulation task.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS during emotion regulation task.
Number of subjects: 20
Study: 33256496

Group type: EXPERIMENTAL
Intervention: Medical cannabis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32209630

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Mirtazapine, Ondansetron, Placebo
Number of subjects: 180
Study: 35240345

Group type: EXPERIMENTAL
Intervention: Informative video intervention (4-minute video detailing cesarean delivery process)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Informative video intervention
Number of subjects: 132
Study: 32312759

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin E (as alpha‐tocopheryl acetate; ATA) daily in VEAPS
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: 50 IU ATA daily in ATBC
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: High-dose vitamin E in VEAPS
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo in VEAPS
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo in ATBC
Number of subjects: 254
Study: 35801770

Group type: EXPERIMENTAL
Intervention: Silicone finger cap
Number of subjects: 11

Group type: COMPARATOR
Intervention: Film dressing
Number of subjects: 11
Study: 34078591

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg immediately after the surgical procedure, and on day 1)
Number of subjects: 1222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1222

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1222
Study: 35477363

Group type: EXPERIMENTAL
Intervention: 3D-printed heart model used for simulated preoperative surgery
Number of subjects: 46

Group type: COMPARATOR
Intervention: Morrow operation without simulated preoperative surgery
Number of subjects: 46
Study: 33165964

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dopamine agonist
Number of subjects: 35
Study: 36418131

Group type: EXPERIMENTAL
Intervention: Clinically assisted hydration (CAH) - parenteral fluids (dextrose saline 4% dextrose, 0.18% sodium chloride)
Number of subjects: 1600
Study: 33822650

Group type: EXPERIMENTAL
Intervention: Intensified clinical pharmacological/pharmaceutical care (medication management and structured patient counseling) over 12 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Intensified clinical pharmacological/pharmaceutical care (intervention group)
Number of subjects: 202
Study: 33942777

Group type: EXPERIMENTAL
Intervention: ropivacaine + dexmedetomidine (1 μg/kg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: ropivacaine + fentanyl (1 μg/kg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: ropivacaine (40 mL/0.5%)
Number of subjects: 138
Study: 32169254

Group type: EXPERIMENTAL
Intervention: Regular alveolar recruitment
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standardised care
Number of subjects: 73
Study: 35384692

Group type: EXPERIMENTAL
Intervention: cART (zidovudine, nevirapine, lamivudine)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No ART
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Antibiotic use
Number of subjects: 49
Study: 34606319

Group type: EXPERIMENTAL
Intervention: Therapeutic anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic anticoagulation
Number of subjects: 0
Study: 32794396

Group type: EXPERIMENTAL
Intervention: Dry dentin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Wet dentin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Both groups (dry and wet dentin)
Number of subjects: 45
Study: 35078280

Group type: EXPERIMENTAL
Intervention: Postoperative exercise rehabilitation training for two weeks
Number of subjects: 74
Study: 32855073

Group type: EXPERIMENTAL
Intervention: Scapular Movement Training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standardized Exercises
Number of subjects: 64
Study: 35833346

Group type: EXPERIMENTAL
Intervention: Direct-to-patient telegenetics
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (telephone/in-person)
Number of subjects: 56
Study: 33826591

Group type: EXPERIMENTAL
Intervention: Mazor robotic-guidance (RG)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Fluoro-guidance (FG)
Number of subjects: 485
Study: 35883122

Group type: EXPERIMENTAL
Intervention: High kinesiophobia (TSK > 37)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low kinesiophobia (TSK ≤ 37)
Number of subjects: 49
Study: 32992531

Group type: EXPERIMENTAL
Intervention: Gerontogymnastics program for 12 weeks
Number of subjects: 216
Study: 35366839

Group type: EXPERIMENTAL
Intervention: Allied health first-contact model
Number of subjects: 56

Group type: COMPARATOR
Intervention: Medical first-contact model
Number of subjects: 56
Study: 33404504

Group type: EXPERIMENTAL
Intervention: Proactively offered online and telephone support services for fruit and vegetables
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Proactively offered online and telephone support services for physical activity
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Proactively offered online and telephone support services for smoking
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Proactively offered online and telephone support services for alcohol use
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Proactively offered online and telephone support services for at least two health behaviors
Number of subjects: 551
Study: 32928528

Group type: EXPERIMENTAL
Intervention: Alcohol detoxification (3-week stay in detoxification ward)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 20
Study: 35023868

Group type: EXPERIMENTAL
Intervention: Full-thickness cartilage strip, incomplete cutting technique
Number of subjects: 63
Study: 33168838

Group type: EXPERIMENTAL
Intervention: Amylase quantification in the terminal ileum; daily analysis of ileostomy effluent for the first 5 post-operative days.
Number of subjects: 11
Study: 35166728

Group type: EXPERIMENTAL
Intervention: Psychological interventions
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Routine care + Psychological interventions
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 200
Study: 33039302

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (n=7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard care physiotherapy (n=8)
Number of subjects: 15
Study: 35142924

Group type: EXPERIMENTAL
Intervention: Monolithic zirconia FPD (Zenostar T, Wieland Dental)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Veneered zirconia FPD (IPS e.max ZirCAD, Ivoclar Vivadent)
Number of subjects: 60
Study: 34348529

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Higher total IL-18 binding protein (IL-18BP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Higher IL-1α
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Higher IL-1R1
Number of subjects: 15
Study: 35477986

Group type: EXPERIMENTAL
Intervention: Electromechanical gait training (30 min/day, 5 days/week for 4 weeks)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional gait training (physical therapist-assisted, 30 min/day, 5 days/week for 4 weeks)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Electromechanical gait training
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional gait training
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Electromechanical gait training and Conventional gait training
Number of subjects: 144
Study: 33858355

Group type: EXPERIMENTAL
Intervention: Controlled Multiple Imputation (MI)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Missing-at-random MI
Number of subjects: 118

Group type: COMPARATOR
Intervention: Controlled MI
Number of subjects: 118
Study: 34883506

Group type: EXPERIMENTAL
Intervention: Clofarabine (CLO) added to induction and consolidation treatment
Number of subjects: 340
Study: 36136773

Group type: EXPERIMENTAL
Intervention: Resilience training (Henderson and Milstein's resilience training package)
Number of subjects: 30
Study: 33745505

Group type: EXPERIMENTAL
Intervention: Tongue-Stabilizing Device (TSD) therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD) therapy
Number of subjects: 39
Study: 33051254

Group type: EXPERIMENTAL
Intervention: Open-lung ventilation (OLV) with recruitment maneuvers (RM) using plateau pressures of 50-60 cmH2O
Number of subjects: 0
Study: 615918947

Group type: EXPERIMENTAL
Intervention: EDOF1 contact lenses (n=15)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: EDOF2 contact lenses (n=21)
Number of subjects: 52

Group type: COMPARATOR
Intervention: SV contact lenses (n=16)
Number of subjects: 52
Study: 35442223

Group type: EXPERIMENTAL
Intervention: Protease inhibitor-based regimen
Number of subjects: 213

Group type: COMPARATOR
Intervention: NNRTI-based regimen
Number of subjects: 213
Study: 33772746

Group type: EXPERIMENTAL
Intervention: 131I therapy for low-risk DTC patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 131I therapy for low-risk papillary thyroid microcarcinomas
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Initial 131I activity for low-risk DTC patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Initial 131I activity for intermediate-risk DTC patients
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Initial 131I activity for high-risk DTC patients
Number of subjects: 135
Study: 32228627

Group type: EXPERIMENTAL
Intervention: Rapid weight loss (RWL) phase (3 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Exercise-only phase (4 days)
Number of subjects: 18
Study: 35904252

Group type: EXPERIMENTAL
Intervention: Bright white light (BWL)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dim red light (DRL)
Number of subjects: 47
Study: 33687578

Group type: EXPERIMENTAL
Intervention: Low PRO-C2 levels
Number of subjects: 253

Group type: COMPARATOR
Intervention: sCT treatment
Number of subjects: 253
Study: 35616795

Group type: EXPERIMENTAL
Intervention: Video-laryngoscope-guided insertion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Blind insertion
Number of subjects: 100
Study: 34256800

Group type: EXPERIMENTAL
Intervention: Methotrexate combined with prednisone
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Certolizumab‐pegol
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 347

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 347
Study: 33065307

Group type: EXPERIMENTAL
Intervention: Second forward view (SFV) examination of the right colon
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Standard withdrawal colonoscopy (SWC) examination
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1011
Study: 33598759

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32437568

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with weekly step goals
Number of subjects: 30
Study: 34610460

Group type: EXPERIMENTAL
Intervention: Parents of children with obesity
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Parents with obesity
Number of subjects: 1862
Study: 33588142

Group type: EXPERIMENTAL
Intervention: WTE incinerator activity (after 3 years)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Farmers living/working near the incinerator
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not exposed)
Number of subjects: 85
Study: 32087025

Group type: EXPERIMENTAL
Intervention: MB score (derived from presence of more than two targeted leads, age of leads, type of leads)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: Low MB score (threshold=1)
Number of subjects: 973

Group type: EXPERIMENTAL
Intervention: High MB score (threshold=5)
Number of subjects: 973
Study: 33615951

Group type: EXPERIMENTAL
Intervention: Daily synbiotic supplement (5 g prebiotic fiber + 8 billion CFU probiotic B. lactis) with 140 mg ferrous sulfate (FeSO4) daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with 140 mg ferrous sulfate (FeSO4) daily for 8 weeks
Number of subjects: 20
Study: 33320058

Group type: EXPERIMENTAL
Intervention: Threshold training (THR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Polarised training (POL)
Number of subjects: 22
Study: 34699693

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Lipusu (LP)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine (GP)
Number of subjects: 490
Study: 34090322

Group type: EXPERIMENTAL
Intervention: Basketball training (2 hours/day, 5 days a week for 8 weeks)
Number of subjects: 34
Study: 32048788

Group type: EXPERIMENTAL
Intervention: 3 sessions per week of acupuncture (group H)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1 session per week of acupuncture (group L)
Number of subjects: 60
Study: 32826268

Group type: EXPERIMENTAL
Intervention: Broad volunteer support, emphasising psychosocial and existential care and signposting tasks
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Narrow volunteer support, emphasising nursing care tasks
Number of subjects: 801

Group type: COMPARATOR
Intervention: PC training
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Multidimensional support
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Practical support
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Training and supervision for volunteers
Number of subjects: 801
Study: 34471000

Group type: EXPERIMENTAL
Intervention: curcuRougeTM (newly developed highly bioavailable curcumin formulation) administered for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33050760

Group type: EXPERIMENTAL
Intervention: Peficitinib 100 mg/day
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Peficitinib 150 mg/day
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Peficitinib (all doses)
Number of subjects: 1052
Study: 32615614

Group type: EXPERIMENTAL
Intervention: Central anatomical single-bundle (SB) reconstruction
Number of subjects: 34

Group type: COMPARATOR
Intervention: Anatomical double-bundle (DB) reconstruction
Number of subjects: 34
Study: 32466776

Group type: EXPERIMENTAL
Intervention: Predicted propofol effect site concentration (AvgCe)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Cognitive impairment (CDR levels)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Baseline cognitive measurements (MMSE, CDR, GDS, AD biomarkers)
Number of subjects: 186
Study: 36097721

Group type: EXPERIMENTAL
Intervention: 3-minute video featuring a Black or White female nurse discussing mental health struggles
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: 3-minute video featuring a Black or White female nurse discussing mental health struggles (booster video watched 14 days later)
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Control video unrelated to mental health
Number of subjects: 1402
Study: 33434399

Group type: EXPERIMENTAL
Intervention: DAV132 7.5 g administered concomitantly with warfarin (5 mg) and clonazepam (1 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DAV132 7.5 g administered 1 hour before warfarin (5 mg) and clonazepam (1 mg)
Number of subjects: 42
Study: 32967874

Group type: EXPERIMENTAL
Intervention: Integrated communication support program for oncologists (2.5-hour training) and patients/caregivers (half-hour coaching)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (CG) with no training
Number of subjects: 200
Study: 36102329

Group type: EXPERIMENTAL
Intervention: OJ + orange pomace (OJ+P, 10g fiber/d)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: AJ + apple pomace (AJ+P, 10g fiber/d)
Number of subjects: 181

Group type: COMPARATOR
Intervention: OJ (0g fiber/d)
Number of subjects: 181

Group type: COMPARATOR
Intervention: AJ (0g fiber/d)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Orange or apple pomace supplementation
Number of subjects: 181
Study: 32554185

Group type: EXPERIMENTAL
Intervention: Delayed Sleep Phase Disorder (DSPD)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Evening chronotype
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Young age, cannabis use, cyclothymic temperamental traits, severe global impairment
Number of subjects: 102
Study: 34746958

Group type: EXPERIMENTAL
Intervention: Falciform ligament wrap around the hepatic artery
Number of subjects: 445

Group type: COMPARATOR
Intervention: No falciform ligament wrap (control)
Number of subjects: 445
Study: 32755526

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for hematocrit
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for granulocyte count
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores for C-reactive protein levels
Number of subjects: 493
Study: 35104387

Group type: EXPERIMENTAL
Intervention: Eccentric MVC
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Concentric MVC
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Isometric MVC
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 34555986

Group type: EXPERIMENTAL
Intervention: Bamlanivimab plus etesevimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35299753

Group type: EXPERIMENTAL
Intervention: Supervised resistance training for 12 weeks during adjuvant chemotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Education to promote lymphatic and venous return, maintain range of motion, and promote physical activity
Number of subjects: 106
Study: 36216140

Group type: EXPERIMENTAL
Intervention: fMRI scanning
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: rs53576 G homozygotes in the neuroimaging arm
Number of subjects: 185

Group type: COMPARATOR
Intervention: Behavioral arm
Number of subjects: 185
Study: 33963004

Group type: EXPERIMENTAL
Intervention: Prongs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nasal mask
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prongs with leak-corrective manoeuvres
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nasal mask with leak-corrective manoeuvres
Number of subjects: 50
Study: 32030906

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Community violence exposure
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Behavioral problems
Number of subjects: 511
Study: 33975171

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Sertraline or Paroxetine
Number of subjects: 390
Study: 32593323

Group type: EXPERIMENTAL
Intervention: Portico valve
Number of subjects: 750

Group type: COMPARATOR
Intervention: Commercially available valve
Number of subjects: 750
Study: 37779358

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus intensive lifestyle therapy
Number of subjects: 1936

Group type: COMPARATOR
Intervention: Conventional lifestyle therapy with placebo
Number of subjects: 1936

Group type: EXPERIMENTAL
Intervention: Intensified lifestyle therapy, pioglitazone, or their combination
Number of subjects: 1936
Study: 33581774

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus capecitabine
Number of subjects: 267

Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine
Number of subjects: 267
Study: 33085711

Group type: EXPERIMENTAL
Intervention: Exposure to anesthesia and abdominal surgery during infancy
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control group (unexposed)
Number of subjects: 485
Study: 35596146

Group type: EXPERIMENTAL
Intervention: LiHuo probiotics with rabeprazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Probiotic placebo with rabeprazole
Number of subjects: 120
Study: 33836215

Group type: EXPERIMENTAL
Intervention: Larger portion of vegetables (120 g)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Flavor enhancement (6.6% light butter and 0.5% salt)
Number of subjects: 67
Study: 35067939

Group type: EXPERIMENTAL
Intervention: Training in elaborative reminiscing
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 33887408

Group type: EXPERIMENTAL
Intervention: MF-PRP HD (High Dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MF-PRP LD (Low Dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MF-Saline
Number of subjects: 30
Study: 33771832

Group type: EXPERIMENTAL
Intervention: Knee bracing (matched to patients' clinical and radiographic presentation and with adherence support)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Advice, written information and exercise instruction
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Knee bracing
Number of subjects: 434
Study: 35023811

Group type: EXPERIMENTAL
Intervention: Graphic 'Haemostasis Traffic Light'
Number of subjects: 84

Group type: COMPARATOR
Intervention: Text-based cognitive aid
Number of subjects: 84
Study: 33876483

Group type: EXPERIMENTAL
Intervention: Silence is Deadly program
Number of subjects: 594

Group type: COMPARATOR
Intervention: Usual classes
Number of subjects: 594